Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma
Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/6/1033 |
| _version_ | 1797592477912268800 |
|---|---|
| author | Matías Tellado Mariangela De Robertis Daniela Montagna Daniela Giovannini Sergio Salgado Sebastián Michinski Emanuela Signori Felipe Maglietti |
| author_facet | Matías Tellado Mariangela De Robertis Daniela Montagna Daniela Giovannini Sergio Salgado Sebastián Michinski Emanuela Signori Felipe Maglietti |
| author_sort | Matías Tellado |
| collection | DOAJ |
| description | Electrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma. |
| first_indexed | 2024-03-11T01:51:38Z |
| format | Article |
| id | doaj.art-fb6e0e92a13a4451bd5a3b3a253d5ca6 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T01:51:38Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-fb6e0e92a13a4451bd5a3b3a253d5ca62023-11-18T12:58:17ZengMDPI AGVaccines2076-393X2023-05-01116103310.3390/vaccines11061033Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant MelanomaMatías Tellado0Mariangela De Robertis1Daniela Montagna2Daniela Giovannini3Sergio Salgado4Sebastián Michinski5Emanuela Signori6Felipe Maglietti7VetOncologia, Veterinary Oncology Clinic, Buenos Aires 1408, ArgentinaDepartment of Biosciences, Biotechnology and Environment, University of Bari ‘A. Moro’, 70125 Bari, ItalyInstituto de Medicina Experimental (IMEX-CONICET), Academia Nacional de Medicina, Buenos Aires 1425, ArgentinaENEA SSPT-TECS-TEB, Casaccia Research Center, Division of Health Protection Technology (TECS), Agenzia Nazionale per le Nuove Tecnologie, l’Energia e lo Sviluppo Economico Sostenibile (ENEA), 00123 Rome, ItalyCREOVet, Veterinary Oncology Clinic, Lima 04, PeruInstituto de Física Interdsiciplinaria y Aplicada (INFINA), Facultad de Cs Exactas y Naturales, UBA-CONICET, Buenos Aires 1428, ArgentinaLaboratory of Molecular Pathology and Experimental Oncology, Institute of Translational Pharmacology, CNR, Rome 0133, ItalyInstituto Universitario de Ciencias de la Salud, Fundación Barceló—CONICET, Buenos Aires 1117, ArgentinaElectrochemotherapy (ECT) is a standard of care in veterinary and human oncology. The treatment induces a well-characterized local immune response which is not able to induce a systemic response. In this retrospective cohort study, we evaluated the addition of gene electrotransfer (GET) of canine IL-2 peritumorally and IL-12 intramuscularly to enhance the immune response. Thirty canine patients with inoperable oral malignant melanoma were included. Ten patients received ECT+GET as the treatment group, while twenty patients received ECT as the control group. Intravenous bleomycin for the ECT was used in both groups. All patients had compromised lymph nodes which were surgically removed. Plasma levels of interleukins, local response rate, overall survival, and progression-free survival were evaluated. The results show that IL-2 and IL-12 expression peaked around days 7–14 after transfection. Both groups showed similar local response rates and overall survival times. However, progression-free survival resulted significantly better in the ECT+GET group, which is a better indicator than overall survival, as it is not influenced by the criterion used for performing euthanasia. We can conclude that the combination of ECT+GET using IL-2 and IL-12 improves treatment outcomes by slowing down tumoral progression in stage III–IV inoperable canine oral malignant melanoma.https://www.mdpi.com/2076-393X/11/6/1033electroporationelectrogene transferimmune responsecancerdogECT |
| spellingShingle | Matías Tellado Mariangela De Robertis Daniela Montagna Daniela Giovannini Sergio Salgado Sebastián Michinski Emanuela Signori Felipe Maglietti Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma Vaccines electroporation electrogene transfer immune response cancer dog ECT |
| title | Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
| title_full | Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
| title_fullStr | Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
| title_full_unstemmed | Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
| title_short | Electrochemotherapy Plus IL-2+IL-12 Gene Electrotransfer in Spontaneous Inoperable Stage III–IV Canine Oral Malignant Melanoma |
| title_sort | electrochemotherapy plus il 2 il 12 gene electrotransfer in spontaneous inoperable stage iii iv canine oral malignant melanoma |
| topic | electroporation electrogene transfer immune response cancer dog ECT |
| url | https://www.mdpi.com/2076-393X/11/6/1033 |
| work_keys_str_mv | AT matiastellado electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT mariangeladerobertis electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT danielamontagna electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT danielagiovannini electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT sergiosalgado electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT sebastianmichinski electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT emanuelasignori electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma AT felipemaglietti electrochemotherapyplusil2il12geneelectrotransferinspontaneousinoperablestageiiiivcanineoralmalignantmelanoma |